NEW HAVEN, Conn.--(BUSINESS WIRE)--Trevi Therapeutics, Inc. (“Trevi”), a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus conditions, today announced that Jennifer Good, President and Chief Executive Officer, will present at the Stifel 2014 Healthcare Conference in New York City on Wednesday, November 19, 2014 at 8:00 am ET, where she will discuss Trevi's corporate strategy, recent Nalbuphine ER data and current pending pivotal trials in uremic pruritus and prurigo nodularis.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
